Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Abdul-Hamid BazarbachiMyriam LabopinAnna Maria RaiolaDidier BlaiseWilliam ArceseStella SantaroneYener KocStefania BramantiAlexander KulaginMi KwonSimona SicaJaime SanzEolia BrissotArnon NaglerFabio CiceriMohamad MohtyPublished in: Cancer (2024)
The authors conclude that ATG alone is a less effective prophylaxis strategy compared to PTCy, however, the combination of PTCy and ATG is superior to either monotherapy. They propose that this combination could be considered a potential new standard of care for GVHD prophylaxis in haplo-SCT for AML.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- healthcare
- palliative care
- low dose
- cell therapy
- high dose
- randomized controlled trial
- clinical trial
- peripheral blood
- stem cells
- acute lymphoblastic leukemia
- combination therapy
- young adults
- pain management
- mesenchymal stem cells
- affordable care act
- study protocol